Pro Medicus Limited Half Year Results

16 Feb 2022; Company Announcement - HY22 Results Final - Acrobat pdf 125k Highlights Revenue from ordinary activities $44.33m – up 40.3% Underlying profit before tax $28.8m – up 53.5% Net profit $20.68m – up 52.7% Cash reserves $76.17m – up $14.91m Company remains debt-free Fully franked interim dividend 10c per share – up 42.9% Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half- year net profit of $20.68 million for the six months to the end of December 2021, 52.7% higher than for the previous corresponding period. Revenue from ordinary activities increased by 40.3% to $44.33 million. The company's cash reserves at 31 December 2021 were $76.17 million, up $14.91 million. Pro Medicus announced a final fully franked interim dividend of 10c per share. The company remains debt-free. During the six months Pro Medicus announced the following key contract wins: Novant Health (A$40 million, 7-year contract), a community-based integrated delivery network that spans three US states. Contract renewal with Allegheny Health (A$12 million, 5-year), a health network in Pittsburgh, Pennsylvania. Further extension of German government hospital to a fourth site. The company continued to make significant progress with all key implementations being on or ahead of schedule, including Intermountain and UCSF. Pro Medicus CEO Dr Sam Hupert said the result represented the strongest half-year revenue and profit results in Pro Medicus’ history, powered by contract wins and renewals in the US and an extension of a European contract to cover new regions. “We thought it was a good result with all our key financial indicators heading in the right direction, not just revenue growth but also profit growth, margin expansion and retained earnings,” he said. “There were two key drivers behind

PME Signs A$25M – 7 Year Contract with NYU Langone Health

11 September 2020; Company Announcement NYU Sept 2020 - Acrobat pdf 118k Highlights PME signs 7-year, A$25M deal with NYU Langone Health NYU Langone ranked in the 10 best hospitals by U.S. News & World Report 2020- 2021 Tier 1 academic institution which includes the renowned NYU Grossman School of Medicine Visage technology to be deployed throughout NYU’s imaging departments replacing systems from legacy vendors Extends PME’s footprint in the tier 1 U.S. academic hospital segment Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 7-year contract with NYU Langone Health (NYU Langone), one of the largest health systems in the state of New York and one of the most respected and innovative healthcare institutions in North America. The contract, based on a transaction-based licensing model, will see the company’s Visage 7 technology implemented across all of NYU Langone’s radiology and subspecialty imaging departments, including breast imaging, replacing all existing legacy PACS with a single centralized instance of the Visage 7 Enterprise Imaging Platform. The implementation will span 6 hospitals and numerous additional locations across the NYU Langone healthcare network. Planning for the rollout is to commence in Q2 FY21, with the first sites scheduled to go-live in Q3 FY21. “NYU Langone completed a thorough selection process that required the final round of vendors to perform extensive on-site pilots. This enabled NYU to assess the differences between systems and, importantly, do so in their production environment, which is the ultimate test of how a product will perform,” said Dr Sam Hupert, Pro Medicus CEO. “Winning this deal further validates our belief that we have a unique and highly differentiated

Pro Medicus Limited Full-Year Results

20 August 2020; Company Announcement - Pro Medicus Limited Full Year Results - Acrobat pdf 118k Highlights Strong growth continues despite restrictions of COVID-19 Revenue from underlying operations $56.8m – up 23.9% Underlying profit before tax $30.2m – up 33.4% Net profit after tax $23.1m – up 20.7% Margins increase to 52.5% Cash reserves $43.4m – up 34.3% Strong balance sheet - No debt Fully franked final dividend 6c per share. Total FY20 dividend up 14.3%. Three key contracts announced during the period Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full- year net profit of $23.1m for the 12 months to the end of June 2020, 20.7% higher than for the previous corresponding period. Underlying profit before tax, which excludes a $3.0m one-off capital sale to the German government in the previous period, was $30.24m, an increase of 33.4%. Revenue from underlying operations, increased by 23.9% to $56.8m. There was solid growth in key jurisdictions – North America (up 23.7%) and Australia (up 19.2%) – while revenue from European operations fell 37.7%, largely as a result of the one-off sale to the German government in the previous period. The company's cash reserves at 30 June 2020 were $43.4m, a rise of 34.3%. Pro Medicus announced a final fully franked dividend of 6c per share, taking total dividends for the year to 12c per share. The company remains debt-free. During the year Pro Medicus announced three key contract wins: Ohio State University, November 2019 – a $9m five-year contract with the Ohio State University Wexner Medical Center, a large multi-disciplinary academic medical centre in Columbus, Ohio. Nines Inc, December 2019 – a $6m five-year deal with Palo Alto-based Nines that will see

Pro Medicus Full-Year FY 2020 Results Webcast Announcement

Leading health imaging company Pro Medicus (ASX: PME) announced its full-year results will be released on Thursday, 20 August 2020. Pro Medicus will also host a webcast conference call on Thursday, 20 August 2020 at 11.00 am (AEST) – please refer to the link below. Webcast Public Link: https://services.choruscall.com.au/webcast/promedicus-200820.html

Interview with Dr. Sam Hupert, CEO Pro Medicus [ASX: PME]

  Interview with Dr Sam Hupert - Acrobat 182kb Northwestern Memorial HealthCare (Northwestern) announcement Operational update Current pipeline and future prospects Monday, 1 June 2020 Q: Today PME announced a $22 million, five-year contract with Chicago based Northwestern Memorial HealthCare (Northwestern). Can you briefly explain the key points of the deal? A: It is a five-year deal, and has the usual structure being transaction-based with committed minimums. It is for our Visage 7 product, which will be deployed across all of Northwestern’s radiology departments. Once completed, they will have a single, enterprise-wide implementation of Visage. Q: Where does this announcement rank with other previous announcements by PME with North American healthcare/hospital networks? A: This certainly ranks up there as one of our most important not only because of the size of the deal, but also because of Northwestern’s standing in the medical and medical research communities. It will also provide us with a key reference site in the Chicago area. Q: The market has been waiting a few months for another major announcement from PME – your last one being the Nines announcement in late December last year. What does this announcement mean for PME? A: We have been telling the market over the past 12 months that our pipeline was the best it has been, both in terms of quantity and quality of prospects. Clearly, Northwestern was one of those opportunities, but there are a number of other prospects that we are continuing to work on. Some are looking at multiple products such as using Visage 7 Open Archive in addition to our Viewer, and there are also those who have expressed a preference for Cloud, so it is a good mix. In terms of

Pro Medicus Limited Half-Year FY 2020 Results Webcast Announcement

Leading health imaging company Pro Medicus (ASX: PME) today announced its half year results will be released on Thursday, 13 February 2020. Pro Medicus will also host a webcast conference call on Thursday, 13 February 2020 at 11.00am – please refer to the link below: Webcast Public Link: https://services.choruscall.com.au/webcast/promedicus-200213.html

Pro Medicus Limited Interim Results

21 February 2019; Company Announcement - Half Year Results 2019 - Acrobat pdf 127k Highlights Revenue $25.3m – up 59.4% Reported after-tax profit $9.1m – up 184.3% Underlying after-tax profit $9.2m – up 79.9% EBIT margins increased to 51.8% Cash reserves $24.7m Company remains debt-free Fully franked interim dividend of 3.5c per share Special fully franked dividend of 2.5c per share Ten-year anniversary of Visage Imaging acquisition Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a first-half after-tax profit of $9.1m for the six months to 31 December 2018, 184.3% higher than for the previous corresponding period. During the period, revenues rose in all key jurisdictions: by 40% in North America, by 30% in Australia, and by 204% in Europe, resulting in revenue for the half increasing by 59.4% to $25.3m. The interim results figures are based on new AASB 15 accounting standards that deal with customer revenue, which will now be deemed to be spread evenly over the period of contracts. Last year’s figures have also been updated for comparison purposes. The company's cash reserves at 31 December 2018 were $24.7m. The company will pay an interim dividend of 3.5c per share and a special dividend of 2.5c. Pro Medicus remains debt-free. Dr Sam Hupert, Pro Medicus CEO, said “The interim result was particularly pleasing in that we saw solid growth in all three major jurisdictions. There was a significant uptick in transaction revenues in the US as a greater number of transactions flowed from our Yale and Mayo implementations, our implementations in Australia are progressing well and our wholly-owned European subsidiary, Visage Imaging GmbH, signed an A$3+million extension to the contract it has with a large German Government Hospital network.” In

Pro Medicus Limited Interim Results

16 February 2018; Company announcement - Pro Medicus Limited Interim Results - Acrobat pdf 101k Highlights Revenue of $16.57m – up 9.0% Underlying after tax profit of $5.42m– up 33.0% Net profit (after currency) of $5.07m– up 5.7% Margins increase to 41.5% Cash reserves $22.80m Company remains debt-free Fully franked interim dividend of 2.5c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a first-half underlying (less currency) after tax profit of $5.42m, 33.0% higher than the previous corresponding period on revenue, which increased 9.0% to $16.57m. Margins increased from 38.5% to 41.5% period on period. Net profit after tax and after currency losses was $5.07m for the six months to 31 December 2017 – 5.7% higher than for the previous corresponding period. The currency loss for the period was $0.35m, as compared with a gain of $0.72m in the previous corresponding period. The company's cash reserves at 31 December 2017 were $22.80m despite a 67.2% increase in the final dividend payout, increased tax payments and greater investment in research and development during the six-month period. The company remains debt-free and announced a fully franked interim dividend of 2.5c per share. During the period, Pro Medicus continued to make strong inroads into the North American market, as evidenced by the $18m contract with Yale New Haven Health (“Yale”), one of North America’s most respected healthcare institutions, signed in November 2017. Dr Sam Hupert, Pro Medicus CEO said, “All of Pro Medicus’ key implementations remain on or ahead of schedule, and revenue from these implementations and the recently announced Yale contract will continue to flow in the months ahead.” Pro Medicus’ European business performed in line with expectations, with increased revenue from several smaller sales to

Go to Top